BIOLASE, Inc. (NASDAQ:BIOL) (“BIOLASE” or the “Company”), a global leader in dental lasers, today announced the pricing of an underwritten public offering consisting of 16,453,569 shares of its common stock and pre-funded warrants to purchase 11,403,571 shares of common stock at a public offering price of $0.35 per share or $0.34 per pre-funded warrant. The pre-funded warrants have an exercise price of $0.01 per share, are exercisable immediately, and will not expire until exercised. The offering is expected to close on January 12, 2023, subject to customary closing conditions.
Salesforce Q3 Earnings Highlights: EPS Beat, Revenue Up 11%, Strong Guidance, ‘Number One AI CRM’ And More
Salesforce Inc (NYSE: CRM) reported third-quarter financial results after the close on Wednesday. Here's a look at the key metrics from the quarter.
